Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 167

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users

Open access
Huestis, Marilyn A., Boyd, Susan J., Heishman, Stephen J., Preston, Kenzie L., Bonnet, Denis, Le Fur, Gerard, Gorelick, David A.·2007·Psychopharmacology

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00213-007-0861-5

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 47

  1. Anggadiredja K, Nakamichi M, Hiranita T, Tanaka H, Shoyama Y, Watanabe S, Yamamoto T (2004) Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade. Neuropsychopharmacology 29:1470–1478 · DOI
  2. Arnone M, Maruani J, Chaperon F, Thiebot MH, Poncelet M, Soubrie P, LeFur G (1997) Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 132:104–106 · DOI · Paper page
  3. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrie P (2003) The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63:908–914 · DOI · Paper page
  4. Carai MA, Colombo G, Gessa GL (2004) Rapid tolerance to the intestinal prokinetic effect of cannabinoid CB1 receptor antagonist, SR 141716 (rimonabant). Eur J Pharmacol 494:221–224 · DOI
  5. Chait LD, Fischman MW, Schuster CR (1985) Hangover effects the morning after marijuana smoking. Drug Alcohol Depend 15:229–238 · DOI
  6. Chaperon F, Thiebot MH (1999) Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol 13:243–281 · DOI · Paper page
  7. Cippitelli A, Bilbao A, Hansson AC, del Arco I, Sommer W, Heilig M, Massi M, Bermudez-Silva FJ, Navarro M, Ciccocioppo R, de Fonseca FR (2005) Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. Eur J Neurosci 21:2243–2251 · DOI
  8. Cleland JG, Ghosh J, Freemantle N, Kaye GC, Nasir M, Clark AL, Coletta AP (2004) Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 6:501–508 · DOI · Paper page
  9. Compton DR, Aceto MD, Lowe J, Martin BR (1996) In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta-9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 277:586–594
  10. de Fonseca FR, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M (2004) The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol 40:2–14 · DOI · Paper page
  11. De Vries TJ, Shaham Y, Homberg JR, Crombag H, Schuurman K, Dieben J, Vanderschuren LJMJ, Schoffelmeer ANM (2001) A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 7:1151–1154 · DOI · Paper page
  12. Derocq JM, Segui M, Marchand J, Le Fur G, Casellas P (1995) Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Lett 369:177–182 · DOI · Paper page
  13. Folstein MF, Luria R (1973) Reliability, validity, and clinical application of the Visual Analogue Mood Scale. Psychol Med 3:479–486 · DOI · Paper page
  14. Fride E, Ginzburg Y, Breuer A, Bisogno T, Di Marzo V, Mechoulam R (2001) Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur J Pharmacol 419:207–214 · DOI
  15. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 252:54–61 · DOI · Paper page
  16. Gessa GL, Orru A, Lai P, Maccioni P, Lecca R, Lobina C, Carai MA, Colombo G (2006) Lack of tolerance to the suppressing effect of rimonabant on chocolate intake in rats. Psychopharmacology (Berl) 185:248–254 · DOI
  17. Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I, Cippitelli A, Nava F, Piomelli D, Rodriguez de Fonseca F (2002) A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 22:9612–9617 · DOI · Paper page
  18. Grotenhermen F (2004) Pharmacology of cannabinoids. Neuro Endocrinol Lett 25:14–23
  19. Hilairet S, Bouaboula M, Carriere D, Le Fur G, Casellas P (2003) Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. J Biol Chem 278:23731–23737 · DOI · Paper page
  20. Howlett AC (1995) Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 35:607–634 · DOI · Paper page
  21. Huang W, Moody DE, Andrenyak DM, Smith EK, Foltz RL, Huestis MA, Newton JF (2001) Simultaneous determination of delta-9-tetrahydrocannabinol and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol inhuman plasma by solid phase extraction and gas chromatography-negative ion chemical ionization-mass spectrometry. J Anal Toxicol 25:531–537 · DOI
  22. Huestis MA, Henningfield JE, Cone EJ (1992a) Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 16:276–282 · DOI · Paper page
  23. Huestis MA, Sampson AH, Holicky BJ, Henningfield JE, Cone EJ (1992b) Characterization of the absorption phase of marijuana smoking. Clin Pharmacol Ther 52:31–41 · DOI · Paper page
  24. Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Frank RA (2001) Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 58:322–330 · DOI · Paper page
  25. Jamshidi N, Taylor DA (2001) Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 134:1151–1154 · DOI · Paper page
  26. Kirkham TC (2003) Endogenous cannabinoids: a new target in the treatment of obesity. Am J Physiol Regul Integr Comp Physiol 284:R343–R344 · DOI
  27. Le Foll B, Goldberg SR (2004) Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport 15:2139–2143 · DOI · Paper page
  28. Le Foll B, Goldberg SR (2005) Cannabinoid CB1 antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 312:875–883 · DOI · Paper page
  29. McMahon LR (2006) Discriminative stimulus effects of the cannabinoid CB(1) antagonist SR 141716A in rhesus monkeys pretreated with Delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl) 188:306–314 · DOI
  30. Mechoulam R, Gaoni Y (1965) A total synthesis of dl-delta-1-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 87:3273–3274 · DOI · Paper page
  31. Navarro M, Carrera MR, Del Arco I, Trigo JM, Koob GF, Rodriguez de Fonseca F (2004) Cannabinoid receptor antagonist reduces heroin self-administration only in dependent rats. Eur J Pharmacol 501:235–237 · DOI
  32. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK (1981) Plasma levels of delta-9-tetrahydrocannabinol after intravenous, oral and smoke administration. NIDA Res Monogr 34:250–256
  33. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK (1982) Single dose kinetics of deuterium labelled delta-1-tetrahydrocannabinol in heavy and light cannabis users. Biomed Environ Mass Spectrom 9:6–10 · DOI
  34. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295:761–775 · DOI · Paper page
  35. Rao GK, Zhang W, Kaminski NE (2004) Cannabinoid receptor-mediated regulation of intracellular calcium by delta(9)-tetrahydrocannabinol in resting T cells. J Leukoc Biol 75:884–892 · DOI
  36. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrie P (2003) Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284:R345–R353 · DOI · Paper page
  37. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P (2004) CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes 28:640–648 · DOI · Paper page
  38. Rinaldi-Carmona MR, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Ferrara P, Soubrie P, Breliere JC, Le Fur GL (1994) SR141716, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240–244 · DOI · Paper page
  39. Simiand J, Keane M, Keane PE, Soubrie P (1998) SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 9:179–181
  40. Tomasini MC, Ferraro L, Bebe BW, Tanganelli S, Cassano T, Cuomo V, Antonelli T (2002) Delta(9)-tetrahydrocannabinol increases endogenous extracellular glutamate levels in primary cultures of rat cerebral cortex neurons: involvement of CB(1) receptors. J Neurosci Res 68:449–453 · DOI
  41. Tseng AH, Craft RM (2004) CB(1) receptor mediation of cannabinoid behavioral effects in male and female rats. Psychopharmacology (Berlin) 172:25–30 · DOI
  42. Turpault S, Kanamaluru V, Lockwood GF, Bonnet D, Newton J (2006) Rimonabant pharmacokinetics in healthy and obese subjects. Clin Pharmacol Ther 79:P50 · doi:10.1016/j.clpt.2005.12.177
  43. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389–1397 · DOI · Paper page
  44. Walker JM, Huang SM (2002) Cannabinoid analgesia. Pharmacol Ther 95:127–135 · DOI · Paper page
  45. Wang L, Liu J, Harvey-White J, Zimmer A, Kunos G (2003) Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci U S A 100:1393–1398 · DOI · Paper page
  46. Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M (1994) Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer’s brains. Neuroscience 63:637–652 · DOI · Paper page
  47. Williams CM, Kirkham TC (1999) Anandamide induces overeating: mediation by central cannabinoid (BC1) receptors. Psychopharmacology 143:315–317 · DOI · Paper page

Cited by

See all 167

Metadata

Authors
Huestis, M. A., Boyd, S. J., Heishman, S. J., Preston, K. L., Bonnet, D., Le Fur, G., & Gorelick, D. A.
Venue
Psychopharmacology
Published
2007-07-10
Volume
194
Issue
4
Pages
505-515
ISSN
  • 0033-3158 (ISSN-L)
  • 1432-2072
OpenAlex
W2073083600
Cited by
167
References
4
FWCI
6.07
Type
journal article
Language
en
Open access
green
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. https://app.cochat.ai/papers/10.1007/s00213-007-0861-5
The paper
Huestis, M. A., Boyd, S. J., Heishman, S. J., Preston, K. L., Bonnet, D., Le Fur, G., & Gorelick, D. A. (2007). Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology. https://doi.org/10.1007/s00213-007-0861-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.